Abstract | AIM: METHODS: RESULTS:
Proteinuria was markedly attenuated in the sulodexide-treated groups. After 4 and 8 weeks only the sulodexide-treated groups showed significant reduction in serum creatinine; while after 12 weeks all the three treatment groups showed significant reduction in serum creatinine. Furthermore, all the three treatment groups showed significant reduction in the scores of glomerular sclerosis and tubulointerstitial fibrosis. The glomerular expression of JG-12 was increased in both the sulodexide group and the sulodexide plus irbesartan group, but not in the irbesartan group. The eNOS mRNA and protein expression was decreased and the tPA mRNA and protein expression was significantly increased in the model group compared with Sham group. Sulodexide, irbesartan, and their combination reversed the decrease of eNOS expression but increased the tPA expression much more compared with model group. CONCLUSION:
|
Authors | Ping Li, Lin-lin Ma, Ru-juan Xie, Yuan-sheng Xie, Ri-bao Wei, Min Yin, Jian-zhong Wang, Xiang-mei Chen |
Journal | Acta pharmacologica Sinica
(Acta Pharmacol Sin)
Vol. 33
Issue 5
Pg. 644-51
(May 2012)
ISSN: 1745-7254 [Electronic] United States |
PMID | 22555371
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiotensin II Type 1 Receptor Blockers
- Biomarkers
- Biphenyl Compounds
- Glycosaminoglycans
- RNA, Messenger
- Tetrazoles
- Triglycerides
- glucuronyl glucosamine glycan sulfate
- Creatinine
- Nitric Oxide Synthase Type III
- Nos3 protein, rat
- Tissue Plasminogen Activator
- Irbesartan
|
Topics |
- Angiotensin II Type 1 Receptor Blockers
(pharmacology)
- Animals
- Biomarkers
(blood)
- Biphenyl Compounds
(pharmacology)
- Blood Pressure
(drug effects)
- Blotting, Western
- Body Weight
(drug effects)
- Creatinine
(blood)
- Disease Models, Animal
- Fibrosis
- Glycosaminoglycans
(pharmacology)
- Immunohistochemistry
- Irbesartan
- Kidney
(drug effects, metabolism, pathology)
- Kidney Failure, Chronic
(blood, drug therapy, etiology, genetics, pathology)
- Male
- Nephrectomy
(methods)
- Nitric Oxide Synthase Type III
(genetics, metabolism)
- Proteinuria
(drug therapy, etiology)
- RNA, Messenger
(metabolism)
- Rats
- Rats, Wistar
- Reverse Transcriptase Polymerase Chain Reaction
- Sclerosis
- Tetrazoles
(pharmacology)
- Time Factors
- Tissue Plasminogen Activator
(genetics, metabolism)
- Triglycerides
(blood)
|